undamentalytics Newsletter
Sign in

Bluejay Diagnostics, Inc. (BJDX) stock

Add to watchlist

Add holding +

NASDAQ: BJDX Nasdaq Health Care Equipment

Bluejay Diagnostics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 1 selling6 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds6 adding, 4 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 13.3% while net income fell 8.0%: a 21pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Latest results: FY2022 Q4

Filed March 28, 2024
Earnings per share
-$2848.00 against an average estimate of -$1360.00: missed by 109.4%

Bluejay Diagnostics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.7%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
May 7, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Agreement
  4. Announcement
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bluejay Diagnostics, Inc. valuation models and calculator

No model value for Bluejay Diagnostics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Bluejay Diagnostics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bluejay Diagnostics, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Bluejay Diagnostics, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2023 −$1360.00 −$2848.00 −109.4%
Sept 2023 −$1344.00 −$3328.00 −147.6%
Jun 2023 −$2240.00 −$4400.00 −96.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
3.3%
of tradable shares
Days to cover
0.2
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
10%
of shares
Held by insiders
2.0%
of shares
Employees
6
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022
Income
Revenue 0
Gross profit 0
EBITDA −9
Operating income −9
Net income −9
Diluted EPS −$9.22
Margins
Gross margin 19.6%
EBITDA margin <−999%
Operating margin <−999%
Net margin <−999%
Free-cash-flow margin <−999%
Cash flow
Cash from operations −8
Capital spending 1
Free cash flow −9
Stock-based pay 0
Free cash flow after stock pay −9
Balance sheet
Cash 10
Total debt 0
Net debt (negative = net cash) −10
Diluted shares 1m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Who owns it

Funds buying and selling
Reported value
$259,343
Institutions reporting
8
Shares held vs prior quarter
▲ 267.4%
Positions opened / closed
5 / 3

Top buyers and sellers, Q2 2026: 6 institutions bought and 4 sold ; the biggest buyer was Armistice Capital, LLC (+131K shares) and the biggest seller Sabby Management, LLC (−29K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Armistice Capital, LLC $157,200 131K 60.6% New
Heights Capital Management, Inc $42,480 35K 16.4% New
Boothbay Fund Management, LLC $32,556 27K 12.6% New
Bank Of America Corp $12,404 10K 4.8% New
Vanguard Fiduciary Trust Co $12,270 10K 4.7% New
Tower Research Capital LLC (TRC) $2,288 2K 0.9% ▲ 10.3%
L1 Global Manager Pty Ltd $144 0K 0.1% 0.0%
Caitong International Asset Management Co., Ltd $1 0K 0.0% ▼ 66.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bluejay Diagnostics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $221,711 6 trades by 6 insiders, last 12 months Insider sales History → $48,913 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $172,798 net buying
Insider Date Trade Shares Price Value
Hrt Financial Lp 10% owner July 10, 2026 Sell 34,938 $1.40 $48,913
Hrt Financial Lp 10% owner July 9, 2026 Buy 64,047 $1.51 $96,711
Dey Svetlana Director March 14, 2026 Buy 12,500 $2.00 $25,000
Zeidman Fred S Director March 14, 2026 Buy 12,500 $2.00 $25,000
Chase Donald R Director March 14, 2026 Buy 12,500 $2.00 $25,000
Dey Indranil President and CEO March 14, 2026 Buy 12,500 $2.00 $25,000
Wurth Douglas Clark Director March 14, 2026 Buy 12,500 $2.00 $25,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around August 13, 2026 estimated from the company's past filing pattern, not announced

  • May 7, 2026
  • March 6, 2026
  • November 9, 2023
  • August 16, 2023
  • May 10, 2023
  • March 20, 2023

Recent SEC filings

Data status

When each part of this page on Bluejay Diagnostics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bluejay Diagnostics, Inc. in brief

What does Bluejay Diagnostics, Inc. do?
Bluejay Diagnostics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Bluejay Diagnostics, Inc.'s stock ticker?
Bluejay Diagnostics, Inc. trades under the ticker BJDX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Bluejay Diagnostics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Armistice Capital, LLC, Heights Capital Management, Inc and Boothbay Fund Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Bluejay Diagnostics, Inc. stock?
Over the last 12 months, Bluejay Diagnostics, Inc.'s directors and officers reported 6 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.